Editorial: Legalizing off-label marketing would compromise safety

04/15/2010 | St. Louis Post-Dispatch

The legalization of off-label marketing of drugs in the spirit of free speech, for which Botox maker Allergan argues in a lawsuit against the FDA, could ultimately threaten consumer safety, according to an editorial of the St. Louis Post-Dispatch. Allergan said banning such marketing is a violation of free-speech rights, and a hearing on the company's case is scheduled this month.

View Full Article in:

St. Louis Post-Dispatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC